In our October issue of Pharmaceutical Executive FEATURES
Cover Story Real World Evidence: Data's New Domain William Looney
Pharm Exec convenes an expert Roundtable to discuss one of the hottest topics in big data today—how to make that data relevant to payers, regulators and the patient through reliance on real-world evidence in driving better health outcomes.
Strategy The Rise of the CFO Strategist Casey McDonald
The role of the biopharma chief financial officer is ever-evolving. “Jack of all, master of none" doesn't cut it. Mastery of far more than the company's balance sheet is a necessity.
Market Access “Huge Sellers” Herald Changes in Japan Drug Pricing
Donald Macarthur
The latest price rules revision is both radical and rare by the government's usual exhaustive standards. What do they mean for pharma players in the world's third-largest market?
ALSO IN THIS ISSUE Major Changes Ahead for Drug User Fees Jill Wechsler
PDUFA VI to enhance FDA staffing, revise fees and expand evidence for drug development.
The Barcelona Brief William Looney
Highlighting the seven key trends in global pharma that drove discussion at this year's CPhI Worldwide event in Spain.
Are You Winning or Losing in Pharma 2.0? Stan Bernard
Answer 12 key questions to determine if your brand team is leveraging today's winning competitive strategies and actions.